Effect of the CCR5 antagonist maraviroc on the occurrence of immune reconstitution inflammatory syndrome in HIV (CADIRIS): A double-blind, randomised, placebo-controlled trial

The Lancet HIV

Volumn 1, Issue 2, 2014, Pages e60-e67

  Sierra Madero, J ^m   Ellenberg, S S ^m   Rassool, Mohammed S ^c   Tierney, Ann ^b   Belaunzarán Zamudio, Pablo F ^a   López Martínez, Alondra ^a   Piñeirúa Menéndez, Alicia ^a   Montaner, L ^m   Azzoni, Livio ^d   Benítez, César Rivera ^e   Sereti, Irini ^f   Andrade Villanueva, Jaime ^g   Mosqueda Gómez, Juan L ^h   Rodriguez, Benigno ⁱ   Sanne, I ^m   Lederman, M ^m   Magana Aquino M ^m   Alanís, Audelia ^a   Arellano, Rosa Brena ^a   Zghaib, Maru ^a   Báez Cruz, Juana Del Carmen ^j   Jezile, Vuyokazi S ^k   Jiménez Vieyra, Iris A ^g   López Segura, Mónica ^l   Martínez, Silvia ^e   Martínez Lozano, Jorge ^j   Herrera, Miguel ^j   Montes Salcedo, Karina E ^g   Webster, Tracey ^m   Schulze, Doreen ^k   Meintjes, Graeme ^m   Calva Mercado, Juan J ^m   Hakim, James ^m   more..

^a INSTITUTO NACIONAL DE CIENCIAS MÉDICAS Y NUTRICIÓN SALVADOR ZUBIRÁN   (Mexico)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

^c UNIVERSITY OF THE WITWATERSRAND   (South Africa)

^d WISTAR INSTITUTE   (United States)

^e HOSPITAL GENERAL DE MÉXICO   (Mexico)

^f NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

^g HOSPITAL CIVIL DE GUADALAJARA FRAY ANTONIO ALCALDE   (Mexico)

^h Centro de Ambulatorio de Prevencion y Atencion en SIDA e Infecciones de Transmision Sexual   (Mexico)

ⁱ CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^j HOSPITAL CENTRAL DR IGNACIO MORONES PRIETO   (Mexico)

^k HELEN JOSEPH HOSPITAL   (South Africa)

^l Hospital General de Leon   (Mexico)

^m Hospital Civil de Guadalajara ^*

more..

Author keywords

[No Author keywords available]

Indexed keywords

EFAVIRENZ; EMTRICITABINE; MARAVIROC; PLACEBO; TENOFOVIR;

ADULT; ARTICLE; CD4 LYMPHOCYTE COUNT; CD8+ T LYMPHOCYTE; CONTROLLED STUDY; DISEASE SEVERITY; DIZZINESS; DOUBLE BLIND PROCEDURE; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE RECONSTITUTION INFLAMMATORY SYNDROME; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; TOXIC HEPATITIS; TREATMENT OUTCOME; VIRUS LOAD;

EID: 84921985871     PISSN: None     EISSN: 23523018     Source Type: Journal    
DOI: 10.1016/S2352-3018(14)70027-X     Document Type: Article

References (46)

1. French MA. HIV/AIDS: immune reconstitution inflammatory syndrome: a reappraisal. Clin Infect Dis 2009; 48: 101-07.
2. Müller M, Wandel S, Colebunders R, Attia S, Furrer H, Egger M, and the IeDEA Southern and Central Africa. Immune reconstitution inflammatory syndrome in patients starting antiretroviral therapy for HIV infection: a systematic review and meta-analysis. Lancet Infect Dis 2010; 10: 251-61.
3. Hoyo-Ulloa I, Belaunzarán-Zamudio PF, Crabtree-Ramirez B, Galindo-Fraga A, Pérez-Aguinaga ME, Sierra-Madero JG. Impact of the immune reconstitution inflammatory syndrome (IRIS) on mortality and morbidity in HIV-infected patients in Mexico. Int J Infect Dis 2011; 15: e408-14.
4. Novak RM, Richardson JT, Buchacz K, et al, and the HIV Outpatient Study (HOPS) Investigators. Immune reconstitution inflammatory syndrome: incidence and implications for mortality. AIDS 2012; 26: 721-30.
5. Grant PM, Komarow L, Andersen J, et al. Risk factor analyses for immune reconstitution inflammatory syndrome in a randomized study of early vs. deferred ART during an opportunistic infection. PLoS ONE 2010; 5: e11416.
6. Naidoo K, Yende-Zuma N, Padayatchi N, et al. The immune reconstitution inflammatory syndrome after antiretroviral therapy initiation in patients with tuberculosis: findings from the SAPiT trial. Ann Intern Med 2012; 157: 313-24.
7. Mudd JC, Murphy P, Manion M, et al. Impaired T-cell responses to sphingosine-1-phosphate in HIV-1 infected lymph nodes. Blood 2013; 121: 2914-22.
8. Grant PM, Komarow L, Lederman MM, et al. Elevated interleukin 8 and T-helper 1 and T-helper 17 cytokine levels prior to antiretroviral therapy in participants who developed immune reconstitution inflammatory syndrome during ACTG A5164. J Infect Dis 2012; 206: 1715-23.
9. Antonelli LRV, Mahnke Y, Hodge JN, et al. Elevated frequencies of highly activated CD4+ T cells in HIV+ patients developing immune reconstitution inflammatory syndrome. Blood 2010; 116: 3818-27.
10. Bourgarit A, Carcelain G, Martinez V, et al. Explosion of tuberculinspecific Th1-responses induces immune restoration syndrome in tuberculosis and HIV co-infected patients. AIDS 2006; 20: F1-7.
11. Mahnke YD, Greenwald JH, DerSimonian R, et al. Selective expansion of polyfunctional pathogen-specific CD4(+) T cells in HIV-1-infected patients with immune reconstitution inflammatory syndrome. Blood 2012; 119: 3105-12.
12. Breton G, Adle-Biassette H, Therby A, et al. Immune reconstitution inflammatory syndrome in HIV-infected patients with disseminated histoplasmosis. AIDS 2006; 20: 119-21.
13. Wong EB, Omar T, Setlhako GJ, et al. Causes of death on antiretroviral therapy: a post-mortem study from South Africa. PLoS One 2012; 7: e47542.
14. Meintjes G, Wilkinson KA, Rangaka MX, et al. Type 1 helper T cells and FoxP3-positive T cells in HIV-tuberculosis-associated immune reconstitution inflammatory syndrome. Am J Respir Crit Care Med 2008; 178: 1083-89.
15. Elliott JH, Vohith K, Saramony S, et al. Immunopathogenesis and diagnosis of tuberculosis and tuberculosis-associated immune reconstitution inflammatory syndrome during early antiretroviral therapy. J Infect Dis 2009; 200: 1736-45.
16. Lederman MM, Penn-Nicholson A, Cho M, Mosier D. Biology of CCR5 and its role in HIV infection and treatment. JAMA 2006; 296: 815-26.
17. Dorr P, Westby M, Dobbs S, et al. Maraviroc (UK-427,857), a potent, orally bioavailable, and selective small-molecule inhibitor of chemokine receptor CCR5 with broad-spectrum anti-human immunodeficiency virus type 1 activity. Antimicrob Agents Chemother 2005; 49: 4721-32.
18. Fätkenheuer G, Pozniak AL, Johnson MA, et al. Efficacy of shortterm monotherapy with maraviroc, a new CCR5 antagonist, in patients infected with HIV-1. Nat Med 2005; 11: 1170-72.
19. Chesney MA, Ickovics JR, Chambers DB, et al. Self-reported adherence to antiretroviral medications among participants in HIV clinical trials: the AACTG adherence instruments. Patient Care Committee & Adherence Working Group of the Outcomes Committee of the Adult AIDS Clinical Trials Group (AACTG). AIDS Care 2000; 12: 255-66.
20. Robertson J, Meier M, Wall J, Ying J, Fichtenbaum CJ. Immune reconstitution syndrome in HIV: validating a case definition and identifying clinical predictors in persons initiating antiretroviral therapy. Clin Infect Dis 2006; 42: 1639-46.
21. Haddow LJ, Easterbrook PJ, Mosam A, et al. Defining immune reconstitution inflammatory syndrome: evaluation of expert opinion versus 2 case definitions in a South African cohort. Clin Infect Dis 2009; 49: 1424-32.
22. CDC. 1993 revised classication system for HIV infection and expanded surveillance case definition for AIDS among adolescents and adults. MMWR Recomm Rep 1992; 41: 1-19.
23. Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. Department of Health and Human Services. January 29, 2008. http://www.aidsinfo.nih.gov/ContentFiles/AdultandAdolescentGL.pdf (accessed May 8, 2008).
24. Division of AIDS Table for Grading Adult Adverse Experiences. Regulatory Operations Center (ROC) (version December 2004). http://roc.s-3.com/members/download/adulttox.pdf (accessed Aug 10, 2008).
25. US FDA. US Food and Drug Administration. Safety. What is a Serious Adverse Event? http://www.fda.gov/safety/medwatch/howtoreport/ucm053087.htm (accessed June 10, 2013).
26. Laureillard D, Marcy O, Madec Y, et al, and the CAMELIA (ANRS 1295-CIPRA KH001) Study Team. Paradoxical tuberculosisassociated immune reconstitution inflammatory syndrome after early initiation of antiretroviral therapy in a randomized clinical trial. AIDS 2013; 27: 2577-86.
27. Chang CC, Sheikh V, Sereti I, French MA. Immune reconstitution disorders in patients with HIV infection: from pathogenesis to prevention and treatment. Curr HIV/AIDS Rep 2014; 11: 223-32.
28. Lawn SD, Meintjes G. Pathogenesis and prevention of immune reconstitution disease during antiretroviral therapy. Expert Rev Anti Infect Ther 2011; 9: 415-30.
29. Beishuizen SJ, Geerlings SE. Immune reconstitution inflammatory syndrome: immunopathogenesis, risk factors, diagnosis, treatment and prevention. Neth J Med 2009; 67: 327-31.
30. Cooper DA, Heera J, Goodrich J, et al. Maraviroc versus efavirenz, both in combination with zidovudine-lamivudine, for the treatment of antiretroviral-naive subjects with CCR5-tropic HIV-1 infection. J Infect Dis 2010; 201: 803-13.
31. Reshef R, Luger SM, Hexner EO, et al. Blockade of lymphocyte chemotaxis in visceral graft-versus-host disease. N Engl J Med 2012; 367: 135-45.
32. Fleishaker DL, Garcia Meijide JA, Petrov A, et al. Maraviroc, a chemokine receptor-5 antagonist, fails to demonstrate efficacy in the treatment of patients with rheumatoid arthritis in a randomized, double-blind placebo-controlled trial. Arthritis Res Ther 2012; 14: R11.
33. Martin-Blondel G, Cuzin L, Delobel P, et al. Is maraviroc beneficial in paradoxical progressive multifocal leukoencephalopathy-immune reconstitution inflammatory syndrome management? AIDS 2009; 23: 2545-46. DOI:10.1097/QAD.0b013e32833365f4.
34. Giacomini PS, Rozenberg A, Metz I, Araujo D, Arbour N, Bar-Or A, and the Maraviroc in Multiple Sclerosis-Associated PML-IRIS (MIMSAPI) Group. Maraviroc and JC virus-associated immune reconstitution inflammatory syndrome. N Engl J Med 2014; 370: 486-88.
35. Hunt PW, Shulman NS, Hayes TL, et al. The immunologic effects of maraviroc intensification in treated HIV-infected individuals with incomplete CD4+ T-cell recovery: a randomized trial. Blood 2013; 121: 4635-46.
36. Gulick RM, Lalezari J, Goodrich J, et al, and the MOTIVATE Study Teams. Maraviroc for previously treated patients with R5 HIV-1 infection. N Engl J Med 2008; 359: 1429-41.
37. Cuzin L, Trabelsi S, Delobel P, et al, and the ANRS 145 MARIMUNO Study group. Maraviroc intensification of stable antiviral therapy in HIV-1-infected patients with poor immune restoration: MARIMUNO-ANRS 145 study. J Acquir Immune Defic Syndr 2012; 61: 557-64.
38. Kaufmann GR, Perrin L, Pantaleo G, et al, and the Swiss HIV Cohort Study Group. CD4 T-lymphocyte recovery in individuals with advanced HIV-1 infection receiving potent antiretroviral therapy for 4 years: the Swiss HIV Cohort Study. Arch Intern Med 2003; 163: 2187-95.
39. Pett SL, Zaunders J, Bailey M, et al. A novel chemokine-receptor-5 (CCR5) blocker, SCH532706, has differential effects on CCR5+CD4+ and CCR5+CD8+ T cell numbers in chronic HIV infection. AIDS Res Hum Retroviruses 2010; 26: 653-61.
40. 3 in Mexico J Acquir Immune Defic Syndr 2010; 53: 582-88.
41. Campbell TB, Smeaton LM, Kumarasamy N, et al, and the PEARLS study team of the ACTG. Efficacy and safety of three antiretroviral regimens for initial treatment of HIV-1: a randomized clinical trial in diverse multinational settings. PLoS Med 2012; 9: e1001290.
42. Tuboi SH, Schechter M, McGowan CC, et al. Mortality during the first year of potent antiretroviral therapy in HIV-1-infected patients in 7 sites throughout Latin America and the Caribbean. J Acquir Immune Defic Syndr 2009; 51: 615-23.
43. Lawn SD, Harries AD, Anglaret X, Myer L, Wood R. Early mortality among adults accessing antiretroviral treatment programmes in sub-Saharan Africa. AIDS 2008; 22: 1897-908.
44. Davies MA, Meintjes G. Assessing the contribution of the immune reconstitution inflammatory syndrome to mortality in developing country antiretroviral therapy programs. Clin Infect Dis 2009; 49: 973-75.
45. Laureillard D, Marcy O, Madec Y, et al, and the CAMELIA (ANRS 1295-CIPRA KH001) Study Team. Paradoxical tuberculosisassociated immune reconstitution inflammatory syndrome after early initiation of antiretroviral therapy in a randomized clinical trial. AIDS 2013; 27: 2577-86.
46. Havlir DV, Kendall MA, Ive P, et al, and the AIDS Clinical Trials Group Study A5221. Timing of antiretroviral therapy for HIV-1 infection and tuberculosis. N Engl J Med 2011; 365: 1482-91.